Oxford Immunotec Global (Oxford Immunotec Global) Debt-to-Equity : 0.05 (As of Sep. 2020)

View and export this data going back to 2013. Start your Free Trial

What is Oxford Immunotec Global Debt-to-Equity?

Oxford Immunotec Global's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2020 was $1.49 Mil. Oxford Immunotec Global's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2020 was $7.19 Mil. Oxford Immunotec Global's Total Stockholders Equity for the quarter that ended in Sep. 2020 was $191.26 Mil. Oxford Immunotec Global's debt to equity for the quarter that ended in Sep. 2020 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Oxford Immunotec Global's Debt-to-Equity or its related term are showing as below:

OXFD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 0.57
Current: 0.05

During the past 9 years, the highest Debt-to-Equity Ratio of Oxford Immunotec Global was 0.57. The lowest was 0.00. And the median was 0.04.

OXFD's Debt-to-Equity is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 0.22 vs OXFD: 0.05

Oxford Immunotec Global Debt-to-Equity Historical Data

The historical data trend for Oxford Immunotec Global's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Immunotec Global Debt-to-Equity Chart

Oxford Immunotec Global Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.41

0.34

0.04

Oxford Immunotec Global Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Debt-to-Equity	Get a 7-Day Free Trial															0.04	0.04	0.04	0.04	0.05

Competitive Comparison of Oxford Immunotec Global's Debt-to-Equity

For the Diagnostics & Research subindustry, Oxford Immunotec Global's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford Immunotec Global's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Oxford Immunotec Global's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Oxford Immunotec Global's Debt-to-Equity falls into.

Oxford Immunotec Global Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Oxford Immunotec Global's Debt to Equity Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.984	+	7.742)	/	213.691
	=	0.04

Oxford Immunotec Global's Debt to Equity Ratio for the quarter that ended in Sep. 2020 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.487	+	7.19)	/	191.259
	=	0.05

Oxford Immunotec Global (NAS:OXFD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Oxford Immunotec Global Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Oxford Immunotec Global's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford Immunotec Global (Oxford Immunotec Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Oxford Immunotec Global PLC (NAS:OXFD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

143 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4SE

Website

http://www.oxfordimmunotec.com

Oxford Immunotec Global PLC is a diagnostic company. It is focused on developing and commercializing proprietary tests for the management of underserved immune regulated conditions. Its products include T-spot TB, T-spot-CMV, T-spot PRT,T-cell extend etc. The company's research and development activities focus on Chronic infections, Transplantation, Autoimmune and Inflammatory disease, Immune oncology.

Executives

Andrew Scott Walton	director	430 SOUTH SPRING STREET, BURLINGTON NC 27215
Mark R. Klausner	director	C/O OXFORD IMMUNOTEC GLOBAL 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Patricia Randall	director	C/O OXFORD IMMUNOTEC GLOBAL 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Richard A Sandberg	director	330 NEVEDA STREET, NEWTON MA 02460-1458
Patrick J Balthrop	director	C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850
Herm Rosenman	director	OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
James R Tobin	director	C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ronald Asbury Andrews	director	5791 VAN ALLEN WAY, CARLSBAD CA 92008
Peter Wrighton-smith	director, officer: Chief Executive Officer	C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON X0 OX14 4RZ
Mclaughlin Matthew T E	officer: Chief Financial Officer	C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Stefan C Linn	officer: Chief Operating Officer	C/O OXFORD IMMUNOTEC GLOBAL 940 INNOVATION DRIVE MILTON PARK ABINGDON X0 OX14 4RZ
Janet Louise Kidd	officer: General Counsel	C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Elizabeth M Keiley	officer: SVP & General Counsel	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Richard M. Altieri	officer: Chief Financial Officer	C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON X0 OX14 4RZ
Richard Wenstrup	officer: Chief Medical Officer	C/O OXFORD IMMUNOTEC GLOBAL, 94C INNOVATION DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RZ